Sirijatuphat, Rujipas, Manosuthi, Weerawat, Niyomnaitham, Suvimol, Owen, Andrew 
ORCID: 0000-0002-9819-7651, Copeland, Katherine Kradangna, Charoenpong, Lantharita, Rattanasompattikul, Manoch, Mahasirimongkol, Surakameth, Wichukchinda, Nuanjun and Chokephaibulkit, Kulkanya
(2022)
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.
EMERGING MICROBES & INFECTIONS, 11 (1).
pp. 2197-2206.
|
PDF
Early treatment of Favipiravir in COVID-19 patients without pneumonia a multicentre, open-labelled, randomized control study.pdf - Published version Download (1MB) | Preview |
Abstract
We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia development. PCR-confirmed SARS-CoV-2-infected patients without pneumonia were enrolled (2:1) within 10 days of symptomatic onset into FPV and control arms. The former received 1800 mg FPV twice-daily (BID) on Day 1 and 800 mg BID 5-14 days thereafter until negative viral detection, while the latter received only supportive care. The primary endpoint was time to clinical improvement, defined by a National Early Warning Score (NEWS) of ≤1. 62 patients (41 female) comprised the FPV arm (median age: 32 years, median BMI: 22 kg/m²) and 31 patients (19 female) comprised the control arm (median age: 28 years, median BMI: 22 kg/m²). The median time to sustained clinical improvement, by NEWS, was 2 and 14 days for FPV and control arms, respectively (adjusted hazard ratio (aHR) of 2.77, 95% CI 1.57-4.88, <i>P </i>< .001). The FPV arm also had significantly higher likelihoods of clinical improvement within 14 days after enrolment by NEWS (79% vs. 32% respectively, <i>P</i> < .001). 8 (12.9%) and 7 (22.6%) patients in FPV and control arms developed mild pneumonia at a median (range) of 6.5 (1-13) and 7 (1-13) days after treatment, respectively (<i>P</i> = .316). All recovered well without complications. We can conclude that early treatment of FPV in symptomatic COVID-19 patients without pneumonia was associated with faster clinical improvement.<b>Trial registration:</b> Thai Clinical Trials Registry identifier: TCTR20200514001.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | COVID-19, Favipiravir, Thailand, antiviral, RdRp inhibitor |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 18 Oct 2022 15:51 |
| Last Modified: | 18 Jan 2023 19:49 |
| DOI: | 10.1080/22221751.2022.2117092 |
| Open Access URL: | https://doi.org/10.1080/22221751.2022.2117092 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3165644 |
Dimensions
Dimensions
